Article Information
History
- April 27, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Yoshiya Tanaka1,*,
- Atsushi Kumanogoh2,
- Tatsuya Atsumi3,
- Tomonori Ishii4,
- Fumitoshi Tago5,
- Mari Aoki5,
- Shintaro Yamamuro5 and
- Shizuo Akira6
- 1University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
- 2Department of Respiratory Medicine and Clinical Immunology, Osaka University Faculty of Medicine Graduate School of Medicine, Osaka, Japan
- 3Department of Rheumatology, Endocrinology, and Nephrology, Hokkaido University, Sapporo, Japan
- 4Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan
- 5Eisai Co., Ltd., Tokyo, Japan
- 6Department of Host Defense, Osaka University Immunology Frontier Research Center, Osaka, Japan
- ↵*Corresponding author: Yoshiya Tanaka, First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu, Fukuoka 807-8555, Japan. Tel.: +81-93-603-1611; Fax. +81-93-691-9334; E-mail: tanaka{at}med.uoeh-u.ac.jp
Posted April 27, 2024.
Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus Erythematosus
